Figure 4.

Secondary outcomes in the candesartan (CAN; red) and amlodipine (AML; blue) groups: (A) plasma renin activity (PRA), (B) plasma angiotensin II (pAT-II), (C) plasma aldosterone concentration (pAC), (D) inflammation (high-sensitivity C-reactive protein [hs-CRP]), (E) oxidative stress (malondialdehyde (MDA)–low-density lipoprotein [LDL]), and (F) remodeling/cell growth (transforming growth factor [TGF]-β1). Analysis of covariance (ANCOVA) was used for the assessment of secondary outcomes. All statistical tests were 2-sided, and P<0.05 was considered significant. Data are the mean±SD.